Citations

Clear

4847 citation(s) found for "Tu, Eric".

The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder
Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Linder, Brian J , Cameron, Anne P. , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Mayo Clinic

Neurourology and Urodynamics | July 16, 2024 | Volume: 43 | Issue: 8 | Pages: 1742-1752

10.1002/nau.25532 | PMID 39010271 Get It

AbstractPurposeThe purpose of this guideline is to provide evidence‐based guidance to clinicians of all specialties on the evaluation, management, and treatment of idiopathic overactive bladder (OAB). The guideline informs the reader on valid diagnostic processes and provides an approach to selecting treatment options for patients with OAB through the shared decision‐making process, which will maximize symptom control and quality of life, while minimizing adverse events and burden of disease.MethodsAn electronic search employing OVID was used to systematically search the MEDLINE and EMBASE databases, as well as the Cochrane Library, for systematic reviews and primary studies evaluating diagnosis and treatment of OAB from January 2013 to November 2023. Criteria for inclusion and exclusion of studies were based on the Key Questions and the populations, interventions, comparators, outcomes, timing, types of studies and settings (PICOTS) of interest. Following the study selection process, 159 studies were included and were used to inform evidence‐based recommendation statements.ResultsThis guideline produced 33 statements that cover the evaluation and diagnosis of the patient with symptoms suggestive of OAB; the treatment options for patients with OAB, including Noninvasive therapies, pharmacotherapy, minimally invasive therapies, invasive therapies, and indwelling catheters; and the management of patients with BPH and OAB.ConclusionOnce the diagnosis of OAB is made, the clinician and the patient with OAB have a variety of treatment options to choose from and should, through shared decision‐making, formulate a personalized treatment approach taking into account evidence‐based recommendations as well as patient values and preferences.
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie, Zhuoer , Komrokji, Rami S. , Al‐Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand , Saygin, Caner , Zeidan, Amer M. , Mendez, Lourdes , Coombs, Catherine C. , Madanat, Yazan F. , Chung, Stephen S. , Badar, Talha , Foran, James M. , Tsai, Charlton , Amanam, Idoroenyi , Deeg, H. Joachim , Adès, Lionel, Osman, Afaf E.G. , Dinner, Shira, Chandhok, Namrata S. , Soong, Deborah, Brunner, Andrew M. , Ferrari, Jacqueline, Pozzi, Sara , Padron, Eric , Patnaik, Mrinal M. , Al‐Kali, Aref , Adès, Lionel , Komrokji, Rami S , Mendez, Lourdes , Zeidner, Joshua F , Madanat, Yazan , Badar, Talha , Griffiths, Elizabeth A. , Al Malki, Monzr M , Lai, Catherine , Arana Yi, Cecilia , Osman, Afaf E G , Abaza, Yasmin , Taylor, Justin , Chandhok, Namrata , Carraway, Hetty E. , Elena, Chiara , Gallì, Anna , Patnaik, Mrinal , Malcovati, Luca , Savona, Michael R , Al-Kali, Aref , Patel, Anand , Xie, Zhuoer , Zeidan, Amer M , Bewersdorf, Jan Philipp , Kishtagari, Ashwin , Zeidner, Joshua F. , Desai, Pinkal , Malki, Monzr M. Al , Lai, Catherine , Yi, Cecilia Arana , Abaza, Yasmin , Singh, Abhay , Malcovati, Luca , Savona, Michael R.

Mayo Clinic

Blood | July 12, 2024 | Volume: 144 | Issue: 19 | Pages: 2033-2044

10.1182/blood.2024024756 | PMID 38996210 Get It

Abstract Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 patients with CCUS investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count of <100 × 109/L (score = 2.5), and ≥2 mutations (score = 3). Variable scores were based on the coefficients from the Cox proportional hazards model. This led to the development of the clonal cytopenia risk score (CCRS), which stratified patients into low- (score of <2.5 points), intermediate- (score of 2.5 to <5), and high-risk (score of ≥5) groups. The CCRS effectively predicted 2-year cumulative incidence of MN for low- (6.4%), intermediate- (14.1%), and high-risk (37.2%) groups, respectively, by the Gray test (P < .0001). We further validated the CCRS by applying it to an independent CCUS cohort of 104 patients, demonstrating a c-index of 0.64 (P = .005) in stratifying the cumulative incidence of MN. Our study underscores the importance of integrating clinical and molecular data to assess the risk of CCUS progression, making the CCRS a valuable tool that is practical and easily calculable. These findings are clinically relevant, shaping the management strategies for CCUS and informing future clinical trial designs.
Fibula Free Flap Reconstruction of Cervical Spine Defects: A Multi‐Institutional Study
Yang, Sara , Morton, Zoey , Colcord, Maddie, Moore, Eric J. , Thuener, Jason E. , Bewley, Arnaud F. , Coughlin, Andrew, Richmon, Jeremy D. , Pipkorn, Patrik , Zender, Chad , Wax, Mark K. , Moore, Eric J , Thuener, Jason , Richmon, Jeremy D , Zender, Chad A , Wax, Mark K , Jackson, Ryan S. , Khariwala, Samir S , Winters, Ryan D. , Militsakh, Oleg N. , III, James M. Wright

Mayo Clinic

The Laryngoscope | July 10, 2024 | Volume: 134 | Issue: 12 | Pages: 4923-4928

10.1002/lary.31625 | PMID 38984420 Get It

IntroductionCervical spine defects result in spinal instability, putting the spinal cord and vertebral arteries at risk of damage and possibly devastating neurological injuries. The fibula free flap can span the spinal defects for stability. There is a paucity of literature on this technique.MethodMulti‐institutional retrospective case series reviewing patients who underwent cervical spine reconstruction with a fibula free flap. Patient demographic information, comorbidities, characteristics of cervical spine defects, and free flap complications were collected.ResultsA total of 1187 fibula free flaps across 10 different institutions were reviewed. Thirteen patients (1.09%) underwent cervical spine reconstruction with a fibula free flap. Average age was 52.3 years old with an age range of 12–79 years. There were six males (46.1%) and seven females (53.8%). The most common defect etiology was infection (n = 6, 46.1%). Most commonly involved cervical spine level of the defect was C5 (n = 10) followed by C6 (n = 9) and C4 (n = 8). The majority of reconstructed defects spanned three or more cervical levels, (n = 9, 69.2%). Facial artery was the most common arterial anastomosis (n = 8). Eight patients (61.5%) required a tracheostomy during their postoperative course. None of the patients had symptomatic or radiographic nonunion.ConclusionThis case series demonstrates that a vascularized fibula flap is a potential reconstructive option for cervical spine defects, especially in defects greater than three cervical levels, in the setting of infection, and previously radiated patients.Level of Evidence4 Laryngoscope, 134:4923–4928, 2024
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).
Collisson, Eric A. , Cusnir, Mike , Winograd, Rafael , Shergill, Ardaman , Ko, Andrew H. , Tsang, Erica S , Shi, Qian , Olive, Kenneth P , Dixon, Jesse G. , Botta, Gregory P. , Wadlow, Raymond Couric , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4205-TPS4205

10.1200/jco.2024.42.16_suppl.tps4205 Get It

TPS4205 Background: Multiple lines of evidence support the use of platinum-based chemotherapy for patients with homologous recombination deficiency-associated pancreatic adenocarcinoma (HRD PDAC; 15-20%). However, the impact of the specific platinum agent used remains uncertain. Mechanistically, oxaliplatin and cisplatin act distinctly on cancer cells, reflected in disparate toxicity profiles and target disease indications; furthermore, preclinical studies have shown that BRCA2-deficient cell lines and mice demonstrate significantly greater sensitivity to cisplatin compared to oxaliplatin. While oxaliplatin, part of the FOLFIRINOX regimen, represents the most commonly used platinum analogue for PDAC, clinical data shows that cisplatin (in combination with gemcitabine) can produce robust response rates (~70%) specifically in patients with germline BRCA/PALB2-mutated metastatic PDAC. We therefore designed a randomized clinical trial (PLATINUM) through the Alliance for Clinical Trials in Oncology cooperative group to assess the optimal chemotherapy regimen in patients with HRD-associated metastatic PDAC following front-line FOLFIRINOX and to test the hypothesis that a platinum switch strategy will be beneficial. Methods: The study consists of a seamless phase II/III design, with the primary endpoint of the phase III component being overall survival. Eligible patients will have metastatic PDAC, a confirmed pathogenic BRCA1/2 or PALB2 mutation (somatic or germline), and demonstrated disease progression on front-line FOLFIRINOX, with or without subsequent PARP inhibitor maintenance. Patients will be randomized 1:1 to receive (1) the de facto standard of gemcitabine plus nab-paclitaxel; or (2) the experimental 3-drug combination of gemcitabine, nab-paclitaxel, and cisplatin (NABPLAGEM), which has been previously studied in non-biomarker-selected patients with advanced biliary tract cancer (SWOG1815) and metastatic PDAC. Both treatment arms will use a once every other week dosing schedule. A total of 100 patients will be enrolled, which provides 90% power to detect an effect size of hazard ratio 0.5 (median OS of 18 vs 9 months) at a one-sided alpha of 0.05. Reports containing efficacy, adverse events, and administrative information will be provided to the Alliance DSMB every 6 months. Planned correlatives include ctDNA analysis for BRCA reversion mutations in all patients, as well as whole genome and transcriptome sequencing in an optional biopsy cohort. This study was activated in December 2023. Clinical trial information: NCT06115499 .
Endoscopic‐assisted transorbital extended orbital exenteration: A multi‐institutional preclinical study
Roccuzzo, Giuseppe , Vyskocil, Erich , Kandathil, Sam Augustine , Peris‐Celda, Maria , Leong, Samuel , Herman, Philippe , Vérillaud, Benjamin , Bresson, Damien, Schreiber, Alberto , Arosio, Alberto Daniele , Valentini, Marco , Pozzi, Fabio , Volpi, Luca , Nicolai, Piero , Ferrari, Marco , Kandathil, Sam Augustine , Borsetto, Daniele , Taboni, Stefano , Mattavelli, Davide , Ferrari, Marco , Schreiber, Alberto , Hirtler, Lena , Agosti, Edoardo , Kuan, Edward C , Wang, Eric W , Sharma, Rishi , Vinciguerra, Alessandro , Bresson, Damien , Erović, Boban M. , Vural, Alperen , Dallan, Iacopo , Doglietto, Francesco , Mattavelli, Davide , Rampinelli, Vittorio , Battaglia, Paolo , Turri‐Zanoni, Mario , Bignami, Maurizio , Castelnuovo, Paolo

Mayo Clinic

Head & Neck | July 3, 2024 | Volume: 46 | Issue: 9 | Pages: 2327-2339

10.1002/hed.27858 | PMID 38958177 Get It

Abstract Background Sinonasal malignancies with orbital invasion have dismal prognosis even when treated with orbital exenteration (OE). Sugawara et al. developed a surgical strategy called “extended‐OE (EOE),” showing encouraging outcomes. We hypothesized that a similar resection is achievable under endoscopic guidance through the exenterated orbit (endoscopic‐EOE). Methods The study was conducted in three institutions: University of Vienna; Mayo Clinic; University of Insubria; 48 orbital dissections were performed. A questionnaire was developed to evaluate feasibility and safety of each step, scoring from 1 to 10, (“impossible” to “easy,” and “high risk” to “low risk,” respectively), most likely complication(s) were hypothesized. Results The step‐by‐step technique is thoroughly described. The questionnaire was answered by 25 anterior skull base surgeons from six countries. Mean, median, range, and interquartile range of both feasibility and safety scores are reported. Conclusions Endoscopic‐EOE is a challenging but feasible procedure. Clinical validation is required to assess real‐life outcomes.
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (L
Molina, Julian R. , Smith, Caleb J. , Welling, Theodore H., Grierson, Patrick , Morelli, Maria Pia , Hecht, J. Randolph, Patel, Sandip Pravin , Weng, Wen-Kai, Vong, Judy, Liechty, Kirstin B., Ng, Eric Wai-Choi , Welch, John S. , Maloney, David G. , Go, William Y., Simeone, Diane M. , Kirtane, Kedar , Locke, Frederick L. , Weng, Wen‐Kai , Fakih, Marwan , Maus, Marcela V , Punekar, Salman R.

Mayo Clinic

Journal of Clinical Oncology | July 2, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS2698-TPS2698

10.1200/jco.2024.42.16_suppl.tps2698 Get It

TPS2698 Background: Chimeric antigen receptor (CAR) T-cell therapies for treating solid tumors are challenging due to a lack of tumor-specific targets that discriminate cancer from normal cells. Previous studies using CEA T-cell receptors and T-cell engagers have resulted in dose-limiting, on-target, off-tumor toxicities (1,2). A2B530 is an autologous logic-gated, CEA-targeted Tmod CAR T-cell therapy that addresses the challenges of on-target, off-tumor toxicity by combining a CAR-activating receptor with a blocking receptor to discriminate tumor from normal cells (3). The activator recognizes CEA on the surface of both tumor and normal cells while specificity for tumor cells is provided by a blocker that binds HLA-A*02. In patients with both germline HLA-A*02 and tumor-associated HLA-A*02 LOH, the blocker prevents on-target, off-tumor toxicity on normal cells owing to retained HLA-A*02 expression (4). HLA-A*02 LOH can be detected using next-generation sequencing (Tempus AI, Inc.). With this definitive discriminator target, A2B530 can potentially provide a therapeutic window to treat patients with CEA-expressing solid tumors exhibiting HLA LOH. Methods: EVEREST-1 (NCT05736731) is a seamless, phase 1/2, open-label, nonrandomized study to evaluate the safety and efficacy of A2B530 in adult patients. Patients are enrolled through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease. BASECAMP-1–eligible patients undergo leukapheresis and, when clinically appropriate, their banked T cells are manufactured for the EVEREST-1 study. The key inclusion criteria include histologically confirmed recurrent unresectable, locally advanced, or metastatic cancers associated with CEA expression: non-small cell lung, colorectal, or pancreatic cancers. Patients should have received ≥1 line of prior therapy such as checkpoint inhibitor, molecular targeted, or chemotherapy. The primary objective of phase 1 is to evaluate the safety and tolerability of A2B530 and determine the recommended phase 2 dose (RP2D). The dose-escalation portion is based on the Bayesian optimal interval design. The dose-expansion phase will confirm RP2D and collect biomarker data to further characterize A2B530. Phase 2 will assess overall response rate per RECIST v1.1. As of January 29, 2024, 8 patients have been enrolled on EVEREST-1. A2B530 was successfully manufactured for all patients, and all patients have received A2B530 infusion, with the first patient dosed in May 2023. Dose escalation is ongoing. 1. Parkhurst, et al. Mol Ther. 2022. 2. Tabernero, et al. J Clin Oncol. 2017. 3. Hamburger, et al. Mol Immunol. 2020. 4. Sandberg, et al. Sci Transl Med. 2022. Clinical trial information: NCT05736731 .
Cannabis in combat sports: position statement of the Association of Ringside Physicians
Stellpflug, Samuel J. , Stolbach, Andrew , Ghorayeb, Joe , Magraken, Erik, Twohey, Eric , Lapoint, Jeff , deWeber, Kevin

Mayo Clinic

The Physician and Sportsmedicine | July 1, 2024 | Volume: 52 | Issue: 5 | Pages: 432-443

10.1080/00913847.2024.2375788 | PMID 38949963 Get It

Diagnosis of acute myocardial infarction in patients with renal failure using high-sensitivity cardiac troponin T
Knott, Jonathan D , Ola, Olatunde , Michieli, Laura De , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Crockford, Erika, Lobo, Ronstan , Slusser, Joshua P. , Rastas, Nicholas, Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Grube, Eric , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Sandoval, Yader , Jaffe, Allan S. , De Michieli, Laura , Slusser, Joshua, Knott, Jonathan , Grube, Eric, Jaffe, Allan S.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | June 30, 2024 | Volume: 13 | Issue: 7 | Pages: 546-558

10.1093/ehjacc/zuae079 | PMID 38954535 Get It

Abstract Aims Diagnosing myocardial infarction (MI) in patients with chronic kidney disease (CKD) is difficult as they often have increased high-sensitivity cardiac troponin T (hs-cTnT) concentrations. Methods and results Observational US cohort study of emergency department patients undergoing hs-cTnT measurement. Cases with ≥1 hs-cTnT increase > 99th percentile were adjudicated following the Fourth Universal Definition of MI. Diagnostic performance of baseline and serial 2 h hs-cTnT thresholds for ruling-in acute MI was compared between those without and with CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2). The study cohort included 1992 patients, amongst whom 501 (25%) had CKD. There were 75 (15%) and 350 (70%) patients with CKD and 80 (5%) and 351 (24%) without CKD who had acute MI and myocardial injury. In CKD patients with baseline hs-cTnT thresholds of ≥52, >100, >200, or >300 ng/L, positive predictive values (PPVs) for MI were 36% (95% CI 28–45), 53% (95% CI 39–67), 73% (95% CI 50–89), and 80% (95% CI 44–98), and in those without CKD, 61% (95% CI 47–73), 69% (95% CI 49–85), 59% (95% CI 33–82), and 54% (95% CI 25–81). In CKD patients with a 2 h hs-cTnT delta of ≥10, >20, or >30 ng/L, PPVs were 66% (95% CI 51–79), 86% (95% CI 68–96), and 88% (95% CI 68–97), and in those without CKD, 64% (95% CI 50–76), 73% (95% CI 57–86), and 75% (95% CI 58–88). Conclusion Diagnostic performance of standard baseline and serial 2 h hs-cTnT thresholds to rule-in MI is suboptimal in CKD patients. It significantly improves when using higher baseline thresholds and delta values.
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.
Geyer, Susan M. , Pederson, Levi , Giri, Sharmila, Little, Richard F. , Gore, Steven D. , Mehta–Shah, Neha , Dinner, Shira, Friedberg, Jonathan W. , Leonard, John P. , Abramson, Jeremy S. , Hsi, Eric D. , Landsburg, Daniel J. , Cherng, Hua‐Jay J. , Kahl, Brad S. , Bartlett, Nancy L.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7012-7012

10.1200/jco.2024.42.16_suppl.7012 Get It

7012 Background: DLBCL with expression of MYC and BCL2 (double expressor lymphoma, DEL), has an adverse prognosis. Venetoclax, an inhibitor of BCL2, was previously studied in combination with R-CHOP. A051701 is a phase II/III randomized trial of chemoimmunotherapy +/- venetoclax in DEL and double hit lymphoma cohorts. Here we report initial phase II results from the DEL cohort. Methods: Patients (pts) age ≥ 18 years (y) with untreated DEL were randomized 1:1 to R-CHOP (Arm 1) or R-CHOP-venetoclax (Arm 2). DEL was defined as MYC expression ≥40% and BCL2 expression ≥50%, without double hit cytogenetics. Enrollment was based on local pathology results that were centrally confirmed. Venetoclax 800 mg was given orally days 4-8 of cycle 1 and days 1-5 of subsequent cycles for up to 6 cycles. All cycles were supported by GCSF or peg-GCSF. The primary endpoint was progression-free survival (PFS) with 84% power to detect a HR of 0.518 corresponding to 2y PFS rate of 65% in Arm 1 and 80% in Arm 2 (1-sided α=0.20). Results: 119 DEL pts were enrolled: 60 Arm 1; 59 Arm 2. Analyses were performed for the modified intent-to-treat population, defined as eligible pts with confirmed DEL histology (n=113; 56 Arm 1, 57 Arm 2). Median age was 64 y (range 22-85); baseline demographic factors were well balanced except for advanced stage (more common in Arm 1; (77% vs 60%, p=0.051). Most pts were non-germinal center B cell-like by immunohistochemistry (Arm 1 72%, Arm 2 58%), high-intermediate/high risk IPI (Arm 1 54%, Arm 2 51%) and ECOG performance status 0-1 (Arm 1 95%, Arm 2 86%). BCL2 rearrangements were detected in 25% and 33% of pts on Arm 1 and Arm 2, respectively. Most pts completed therapy per protocol (84% Arm 1, 75% Arm 2). Median follow up is 27 months (m). No difference in PFS was observed with 12-m PFS estimates of 77% in Arm 1, 76% in Arm 2 [HR = 0.98 (95% CI: 0.48 – 2.01), p=0.95]. The end of treatment (EOT) overall and complete response rates among patients with an EOT assessment were 87.5% and 70% in Arm 1, and 90% and 82% in Arm 2. Overall survival (OS) was not statistically significantly different with 12-mo OS estimates of 94% in Arm 1 and 79% in Arm 2 [HR = 1.27 (95% CI: 0.57 – 2.79), p=0.56]. Grade ≥3 adverse events (AEs) occurred more frequently in Arm 2 (42% vs 76%). The most commonly increased grade ≥3 AEs included neutropenia (20% vs 47%), anemia (4% vs 25.5%), thrombocytopenia (5.5% vs 24%), febrile neutropenia (7% vs 16%) and fatigue (0% vs 11%). No grade 5 AEs on treatment were reported on Arm 1, and 3 were reported on Arm 2 (lung infection and sudden death NOS, both possibly related; respiratory failure, unlikely related). Conclusions: Adding venetoclax to R-CHOP in DEL pts did not improve PFS and resulted in increased toxicity. The study did not meet its primary endpoint in phase II, and so did not proceed to phase III. Clinical trial information: NCT03984448 .
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Tarantino, Paolo , Tayob, Nabihah , Villacampa, Guillermo , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Garrett, Audrey Merrill, Albain, Kathy S. , DeFusco, Patricia, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero‐Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn J. , Waks, Adrienne G., DeMeo, Michelle K. , Burstein, Harold J. , Dell’Orto, Patrizia , Russo, Leila, Krause, Emma , Newhouse, Daniel , Schneider, Bryan P. , Krop, Ian E. , Tolaney, Sara M. , Curigliano, Giuseppe , Hui, Winnie W. , Kirkup, Christian , Viale, Giuseppe , Prat, Aleix , Isakoff, Steven J , Mulvey, Therese Marie , Bose, Ron , Wolff, Antonio C , Reeder-Hayes, Katherine , Rugo, Hope S , Zuckerman, Dan , Gadi, Vijayakrishna K , Cheng, Kit , Marcom, Paul Kelly , Albain, Kathy , Tung, Nadine , Nanda, Rita , Jankowitz, Rachel C , Rimawi, Mothaffar , Abramson, Vandana G , Van Poznak, Catherine , Forero-Torres, Andres , Liu, Minetta , Ruddy, Kathryn J , Burstein, Harold J , Partridge, Ann H , Krause, Emma , Kurt, Busem Binboğa , Mittendorf, EA , Schneider, Bryan , Prat, Aleix , Winer, Eric , Krop, Ian E , Tolaney, Sara , Prat, Aleix , Curigliano, Giuseppe , Pohlmann, Paula , Yardley, Denise Aysel , Wolff, Antonio C. , Rugo, Hope S. , Tung, Nadine , Abramson, Vandana G. , Waks, Adrienne G. , Partridge, Ann H. , Winer, Eric P. , Barroso‐Sousa, Romualdo , DiLullo, Molly K. , Zheng, Yue

Mayo Clinic

Journal of Clinical Oncology | June 27, 2024 | Volume: 42 | Issue: 31 | Pages: 3652-3665

10.1200/jco.23.02170 | PMID 38935923 Get It

PURPOSE Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). Coprimary objectives were to compare the incidence of clinically relevant toxicities between arms and to evaluate invasive disease-free survival (iDFS) with T-DM1. Correlative analyses included the HER2DX genomic tool, multiomic evaluations of HER2 heterogeneity, and predictors of thrombocytopenia. RESULTS After a median follow-up of 5.8 years, 11 iDFS events were observed in the T-DM1 arm, consistent with a 5-year iDFS of 97.0% (95% CI, 95.2 to 98.7). At 5 years, the recurrence-free interval (RFI) was 98.3% (95% CI, 97.0 to 99.7), the overall survival was 97.8% (95% CI, 96.3 to 99.3), and the breast cancer-specific survival was 99.4% (95% CI, 98.6 to 100). Comparable iDFS was observed with T-DM1 irrespective of tumor size, hormone receptor status, centrally determined HER2 immunohistochemical score, and receipt of T-DM1 for more or less than 6 months. Although ATEMPT was not powered for this end point, the 5-year iDFS in the TH arm was 91.1%. Among patients with sufficient tissue for HER2DX testing (n = 187), 5-year outcomes significantly differed according to HER2DX risk score, with better RFI (98.1% v 81.8%, hazard ratio [HR], 0.10, P = .01) and iDFS (96.3% v 81.8%, HR, 0.20, P = .047) among patients with HER2DX low-risk versus high-risk tumors, respectively. CONCLUSION Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.